Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
The prevalence of kidney disease (KD) among the general population and in patients with cardiovascular disease (CVD) is high and growing.1 Also, standard therapeutic strategies may act differently in patients with KD, making extrapolation of trial data from patients without KD unreliable.2 In addition, trials in nephrology are more likely to be smaller and unblinded, leading to poorer-quality evidence.3 Despite the need for high-quality evidence for CVD interventions, 2 systematic reviews using data from 1985-2005 and 1998-2005 showed that patients with KD are underrepresented in randomized clinical trials of CVD interventions.4,5 We aimed to update the estimates of the representation of patients with KD in major randomized clinical trials of CVD interventions.
Konstantinidis I, Nadkarni GN, Yacoub R, Saha A, Simoes P, Parikh CR, Coca SG. Representation of Patients With Kidney Disease in Trials of Cardiovascular InterventionsAn Updated Systematic Review. JAMA Intern Med. 2016;176(1):121-124. doi:10.1001/jamainternmed.2015.6102